The study, which took place at five centers, consisted of 113 pediatric patients, with 59 patients receiving treatment with Cutivate and 54 patients receiving treatment with mid-strength steroid EpiCeram. After 28 days of treatment, the study demonstrated that there were no significant differences between the two treatments, with both providing improvement.
EpiCeram’s non-steroidal formulation has a very favorable safety profile and does not have the duration of use restrictions or pediatric patient age restrictions of these other classes of prescription products, Ceragenix said.
Steve Porter, Ceragenix’s chairman and CEO, said: “We have just demonstrated that EpiCeram is comparable to a mid strength steroid in treating the symptoms of atopic dermatitis after a 28 day treatment regimen. We believe that EpiCeram has the potential to become the foundation of a new and improved paradigm in the treatment of this common childhood skin disorder which affects over 15 million Americans.”